Bill Hoon Chang, M.D., Ph.D.
- Email:
- click here
- Phone:
- 503 418-5150
- Office:
- 503 494-0829
PubMed Listing: http://www.ncbi.nlm.nih.gov/sites/entrez?db=pubmed&cmd=DetailsSearch&term=Chang,+Bill[Full+Author+Name]&log$=activity
Assistant Professor
Background
Dr. Chang's research focuses on understanding the biochemical mechanism responsible for resistance in refractory and relapse leukemias. Identifying these mechanisms will aid in the development of new therapies for these resistant diseases. Using RNA interference technologies he has been able to identify new biochemical targets for therapy. Dr. Chang's research continues in collaboration with the Children's Oncology Group to develop these targets for new therapies to these cancers.
Selected Publications
"Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening,"
"Crosstalk between ROR1 and the Pre-B Cell Receptor Promotes Survival of t(1;19) Acute Lymphoblastic Leukemia,"
"Abnormal developmental control of replication-timing domains in pediatric acute lymphoblastic leukemia,"
"In vitro sensitivity to dasatinib in lymphoblasts from a patient with t(17;19)(q22;p13) gene rearrangement pre-B acute lymphoblastic leukemia,"
"Imatinib resistant BCR-ABL1 mutations at relapse in children with Ph +ALL: A Children's Oncology Group (COG) study,"
